Evolution of gastric surgery techniques and outcomes by unknown
Shiozaki et al. Chin J Cancer  (2016) 35:69 
DOI 10.1186/s40880-016-0134-y
REVIEW
Evolution of gastric surgery techniques 
and outcomes
Hironori Shiozaki1, Yusuke Shimodaira1, Elena Elimova1, Roopma Wadhwa1, Kazuki Sudo2, Kazuto Harada1, 
Jeannelyn S. Estrella3, Prajnan Das4, Brian Badgwell5 and Jaffer A. Ajani1*
Abstract 
Surgical management of gastric cancer improves survival. However, for some time, surgeons have had diverse opin-
ions about the extent of gastrectomy. Researchers have conducted many clinical studies, making slow but steady 
progress in determining the optimal surgical approach. The extent of lymph node dissection has been one of the 
major issues in surgery for gastric cancer. Many trials demonstrated that D2 dissection resulted in greater morbidity 
and mortality than D1 dissection. However, long-term outcomes demonstrated that D2 dissection resulted in longer 
survival than D1 dissection. In 2004, the Japan Clinical Oncology Group reported a pivotal trial which was performed 
to determine whether para-aortic lymph node dissection combined with D2 dissection was superior to D2 dissec-
tion alone and found no benefit of the additional surgery. Gastrectomy with pancreatectomy, splenectomy, and 
bursectomy was initially recommended as part of the D2 dissection. Now, pancreas-preserving total gastrectomy 
with D2 dissection is standard, and ongoing trials are addressing the role of splenectomy. Furthermore, the feasibility 
and safety of laparoscopic gastrectomy are well established. Survival and quality of life are increasingly recognized as 
the most important endpoints. In this review, we present perspectives on surgical techniques and important trials of 
these techniques in gastric cancer patients.
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Background
Gastric cancer (GC) is an aggressive malignancy. In 2012, 
according to the World Health Organization GLOBO-
CAN database, it affected 952,000 people and resulted 
in 723,000 deaths [1]. Although the death rate for GC is 
high, it has decreased gradually over the past few decades 
[2]. GC is common in Asia, South America, and Cen-
tral and Eastern Europe but uncommon in other parts 
of Europe, North America, and most parts of Africa [1, 
3]. GC is a common cancer in Japan, with higher over-
all mortality than that in other countries [4–7]. Thus, 
owing to extensive experience in treating GC, Japanese 
surgeons have been leading the surgical management of 
GC and recommend extended lymph node dissection. In 
2001, physicians in Japan established guidelines for the 
treatment of GC, along with the extent of lymph node 
dissection. These guidelines have undergone occasional 
revision, with the latest English version published in 2013 
[8]. This review focuses on dissection of lymph nodes, 
resection of organs surrounding the stomach, and laparo-
scopic surgery in GC patients.
Definition of lymph node dissection
According to National Comprehensive Cancer Network 
guidelines (version 2.2013), “D1 dissection entails gas-
trectomy and resection of both the greater and lesser 
omenta (which would include the lymph nodes along 
right and left cardiac, along lesser and greater curva-
ture, suprapyloric along the right gastric artery, and 
infrapyloric areas). The D2 dissection would include D1 
nodes and all nodes along the left gastric artery, com-
mon hepatic artery, celiac artery, splenic hilum, and 
splenic artery.” [9]. D3 surgery additionally dissects D1 
and D2 lymph nodes along with lymph nodes in the 
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hepatoduodenal ligament and retropancreatic region and 
surrounding the superior mesenteric vein.
Lymph node dissection
The Medical Research Council in the United Kingdom 
conducted a prospective multicenter randomized con-
trolled trial (RCT) with 200 patients in each arm who 
underwent D1 or D2 dissection and total or subtotal gas-
trectomy and reported the results in 1996 [10]. Postop-
erative morbidity (46% vs. 28%, P < 0.001) and mortality 
(13.0% vs. 6.5%, P =  0.04) were higher in the D2 group 
than in the D1 group [10]. The follow-up data demon-
strated no difference in the overall survival (OS) rate 
between the two groups (35% vs. 33%, P = 0.43) [11].
In 1995 the Dutch Gastric Cancer Group performed 
a prospective multicenter RCT with 711 patients who 
underwent D1 or D2 node dissection (380 in the D1 arm 
and 331 in the D2 arm) and gastrectomy [12]. The D2 
group had higher postoperative morbidity and mortal-
ity and longer hospitalization times than the D1 group. 
However, the 5-year OS rates were similar (45% for the 
D1 group and 47% for the D2 group, P = 0.99) [13]. After 
11  years of follow-up, the OS rates did not differ sig-
nificantly between the D1 and D2 groups (30% vs. 35%, 
P = 0.53) [14]. 15-year follow-up analysis demonstrated 
markedly more GC-related deaths in the D1 group; in 
addition, local and regional recurrence rates were higher 
in the D1 group than in the D2 group (22% vs. 12% and 
19% vs. 13%, respectively) [15].
In 1994, the Italian Gastric Cancer Study Group con-
ducted a phase II RCT of D1 and D2 dissection in GC 
patients [16, 17]. It demonstrated postoperative morbid-
ity and mortality in the D2 and D1 groups (20.9% and 
3.1%, respectively) similar to those reported previously 
[15]. In that trial, as opposed to prior trials, the investi-
gators did not perform pancreatectomy. Based on these 
results, the Italian Gastric Cancer Study Group per-
formed another RCT to compare gastrectomy with D1 
and D2 dissection and reported the short-term results 
in 2010, which demonstrated no significant differences 
in postoperative morbidity or mortality between the two 
groups [18]. Follow-up analysis demonstrated no differ-
ences in the 5-year OS rate [19]. In subgroup analyses, 
the D1 group had a higher 5-year disease-specific sur-
vival rate in patients with pathologic T1 disease than 
the D2 group (98% vs. 83%, P = 0.015), whereas the D2 
group had a higher 5-year disease-specific survival rate in 
patients with pathologic T2-4 disease and cancer-positive 
lymph nodes than the D1 group (59% vs. 38%, P = 0.055) 
(Table 1). However, such ad hoc results are not reliable.
In 2006 researchers in Taiwan, China conducted a 
single-center RCT comparing D1 and D3 dissections 
in combination with gastrectomy [20]. They randomly 
assigned 221 eligible patients to D1 or D3 dissection per-
formed by 11 specially trained surgeons, each of whom 
had performed at least 25 independent D3 dissections. 
D3 dissection resulted in a significantly higher 5-year 
OS rate than D1 dissection (59.5% vs. 53.6%, P = 0.041), 
although the morbidity was higher in the D3 group. A 
follow-up study demonstrated that the quality of life did 
not differ between the two groups [21]. The authors con-
cluded that D3 dissection performed by an experienced 
surgeon may offer a survival benefit for patients with GC. 
However, this conclusion contradicts the 2010 Japanese 
GC treatment guidelines (version 3) [6].
In comparison, the Japan Clinical Oncology Group 
(JCOG) conducted an RCT (JCOG9501) comparing the 
outcomes between the two groups treated with gastrec-
tomy plus D2 dissection alone and gastrectomy plus both 
D2 and para-aortic nodal dissections and reported the 
results in 2004 [22]. In their study, 523 eligible patients 
underwent the surgery performed by experienced sur-
geons. The follow-up results demonstrated no difference 
in 5-year OS rate (69.2% for the D2 group vs. 70.3% for 
the D2 and para-aortic nodal dissection group, P = 0.85) 
or recurrence-free survival rate (62.6% for the D2 group 
vs. 61.7% for the D2 and para-aortic nodal dissection 
group, P = 0.56) [23].
Table 1 Randomized trials of lymph node dissection in patients with gastric cancer: D1 vs. D2
– no data available, OS overall survival, RR recurrence rate




Morbidity (%) Mortality (%) 5-year OS  
rate (%)
15-year follow-up (%)
OS rate Local RR Regional RR
Cuschieri et al. [10, 11] D1 200 27.5 6.5 35.0 – – –
D2 200 46.0 13.0 33.0 – – –
Bonenkamp et al. 
[12–14]
D1 380 24.7 3.9 45.0 21.6 21.6 19.2
D2 331 42.9 9.7 47.0 27.8 12.1 13.0
Degiuli et al. [18, 19] D1 133 12.0 3.0 66.5 – – –
D2 134 17.9 2.2 64.2 – – –
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Splenectomy and pancreatectomy
The purpose of gastrectomy with splenectomy or pan-
createctomy along with D2 dissection is the performance 
of comprehensive surgery. Whether to perform splenec-
tomy and pancreatectomy in GC patients has long been a 
subject of debate. In 1999, the Medical Research Council 
conducted a multivariate analysis showing that pancrea-
ticosplenectomy was independently associated with poor 
survival (hazard ratio 1.53, 95% confidence interval 1.17–
2.01) but that splenectomy was not (hazard ratio 1.36, 
95% confidence interval 0.97–1.90) [11]. Also, a Dutch 
Gastric Cancer Group trial published in 2004 suggested 
that D2 dissection, splenectomy, pancreatectomy, and 
older patient age (>70  years) were associated with high 
morbidity and mortality [14].
Investigators in Japan conducted an RCT comparing 
total gastrectomy plus D2 lymph node dissection with 
and without pancreatectomy in 2004 [24]. They rand-
omized 110 patients equally to two groups: one group 
underwent total gastrectomy with removal of the pan-
creatic body and tail as well as the spleen; the other 
group underwent total gastrectomy with splenectomy. 
Although the 5-year OS rates in the two groups did not 
differ significantly, 6% (1 of 18) of the patients in the pan-
createctomy group had diabetes mellitus, 33% (6 of 18) of 
whom were diagnosed as having impaired glucose toler-
ance 1 year after surgery, which occurred with markedly 
higher frequency compared with those in the group with-
out pancreatectomy.
In a prospective RCT comparing total gastrectomy 
with and without splenectomy in 187 patients in Chile 
in 2002 [25], 90 patients underwent total gastrectomy 
with D2 dissection and splenectomy, whereas 97 patients 
did so without splenectomy. The mortalities for those 
who underwent D2 dissection with and without sple-
nectomy were not significantly different (3.1% vs. 4.4%, 
P  >  0.7). Also, the morbidity was higher in the patients 
treated with splenectomy than in those without [fever 
higher than 38 degree, 50% vs. 39% (P < 0.04); pulmonary 
complications, 39% vs. 24% (P  <  0.08); and subphrenic 
abscess, 11% vs. 4% (P  <  0.05)]. The 5-year OS rate did 
not differ significantly in patients undergoing D2 dissec-
tion with and without splenectomy (42% vs. 36%, P > 0.5). 
The authors stated that splenectomy was not necessary.
In 2006, Korea researchers conducted a single-center 
RCT of gastrectomy with and without splenectomy 
[26]. They randomly assigned 207 eligible patients with 
resectable GC to splenectomy (104 patients) and spleen-
preserving (103 patients) groups. No significant differ-
ences in the postoperative morbidity and mortality were 
observed between the splenectomy group and the spleen-
preserving group [15.4% vs. 8.7% (P = 0.142) and 1.9% vs. 
1.0% (P =  1.000), respectively]. The 5-year OS rate was 
not significantly higher in the splenectomy group than in 
the spleen-preserving group (54.8% vs. 48.8%, P = 0.503).
Based on these results, in 2002, a multicenter RCT in 
Japan to determine whether gastrectomy without sple-
nectomy is suitable as a standard surgical treatment of 
GC (JCOG0110) has completed accrual, and the results 
are pending.
Bursectomy
A bursectomy is a dissection of the peritoneal lining 
covering the pancreas and the anterior aspect of the 
transverse mesocolon. In 1980s, physicians in Japan 
performed bursectomy with radical gastrectomy and 
extended dissection, which meant complete resection 
of the post-gastric cavity lining and may have included 
free cancer cells and/or micrometastases [27]. However, 
it increased the risk of surgical complications. Therefore, 
according to the guidelines of the Japanese Gastric Can-
cer Association, bursectomy is recommended only for 
GC with serosal invasion.
In 2012, the interim results of an RCT regarding the 
survival benefit of bursectomy were published [28]. Two 
hundred ten patients with resectable GC were registered 
and underwent total or distal subtotal gastrectomy and 
D2 dissection as standard treatment. One hundred four 
patients underwent the standard procedure with bur-
sectomy, whereas 106 patients underwent the standard 
procedure without bursectomy. The overall morbidity 
(14.30%) and mortality (0.95%) were the same in both 
groups. The difference in 3-year OS rate was not statisti-
cally significant between the two groups with and with-
out bursectomy (85.6% vs. 79.6%, P =  0.443). Also, the 
difference in 3-year OS rate was not statistically different 
between 48 patients with serosa-positive GC treated with 
and without bursectomy (69.8% vs. 50.2%, P  =  0.043). 
However, patients who did not undergo bursectomy 
had more peritoneal recurrences than patients who did 
undergo bursectomy (13.2% vs. 8.7%). Long-term results 
showed that the 5-year OS rates were 77.5% and 66.6% in 
the bursectomy and non-bursectomy groups, respectively 
(two-sided, P = 0.16 for superiority; one-sided, P = 0.99 
for noninferiority). The final results of the analysis did not 
demonstrate the noninferiority of the standard procedure 
without bursectomy. Therefore, the JCOG is conducting a 
large multicenter RCT to evaluate bursectomy in patients 
with T3 (subserosal) or T4 (serosal) GC (JCOG1001), 
which aims to recruit 1200 patients who will undergo 
gastrectomy and D2 dissection with or without bursec-
tomy followed by chemotherapy. The primary endpoint 
is OS; the secondary endpoints are recurrence-free sur-
vival, blood loss, operation time, morbidity, mortality, 
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and the rate of adverse effects of adjuvant chemotherapy. 
The results of this trial are eagerly awaited.
Laparoscopic surgery
Laparoscopic gastrectomy has been popular since 2000s, 
and some RCTs assessed the benefit of the laparoscopic 
procedure. For example, investigators in Japan performed 
an RCT comparing laparoscopy-assisted distal gastrec-
tomy (LADG) with open distal gastrectomy (ODG) in 
2002 [29]. In this study, 28 patients with early-stage GC 
underwent LADG or ODG with D1 dissection. Patients 
in the LADG group had less blood loss but longer opera-
tion time than the ODG group. The number of lymph 
nodes examined was not significantly different between 
the LADG and ODG groups [20.2 vs. 24.9, P = not signif-
icant (NS)]. Furthermore, bowel function and ambulation 
of patients in the LADG group recovered earlier than 
those in the ODG group (bowel function, 1.8 vs. 2.6 days, 
P < 0.05; ambulation, 2.9 vs. 3.9 days, P < 0.05).
In 2005, researchers conducted a similar prospective 
RCT recruited only 28 patients with GC [30]. The opera-
tion time was longer in the LADG group than in the 
ODG group (378 vs. 235 min, P < 0.01), and the postop-
erative hospital stay was shorter in the LADG group than 
in the ODG group (12 ± 2 vs. 18 ± 6 days, P < 0.01).
At the same time, researchers in Korea conducted 
a single-center RCT [31]. They randomly assigned 47 
patients with early-stage GC to undergo either LADG 
(n = 24) or ODG (n = 23). The mean operation time was 
longer in the LADG group than in the ODG group (319.6 
vs. 190.4 min, P < 0.001). However, the postoperative pul-
monary complication rate was lower in the LADG group 
than in the ODG group (8% vs. 30%, P = 0.045). In com-
parison, investigators in Italy performed a single-center 
RCT comparing the feasibility and OS of 59 patients with 
GC in the LADG and ODG groups [32]. They observed 
no significant differences between the LADG and ODG 
groups in the study endpoints, including morbidity 
(23.3% vs. 27.6%, P = NS) and mortality (3.3% vs. 6.9%, 
P = NS). The times from the operation to resumption of 
oral intake and to discharge were shorter in the LADG 
group (oral intake: 5.1 vs. 7.4 days, P < 0.001; discharge: 
10.3 vs. 14.5 days, P < 0.001). In addition, the 5-year OS 
rates (58.9% vs. 55.7%, P = NS) and the 5-year disease-
free survival rates (57.3% vs. 54.8%, P = NS) were similar.
In 2008, an RCT conducted in Korea to assess the 
quality of life of GC patients after LADG or ODG 
(COACT 0301) [33] showed that blood loss in the LADG 
group was lower than that in the ODG group (111.6 
vs. 267.2 mL, P < 0.05) but that the operation time was 
longer (378 vs. 235 min, P < 0.01) and the number of dis-
sected lymph nodes was smaller (39.0 vs. 45.1, P < 0.05) 
in the LADG group. The LADG group experienced 
earlier weaning from epidural anesthesia (39.4 vs. 
47.8  mL, P  <  0.001), earlier resumption of oral intake 
(3.8 vs. 4.1 days, P = 0.002), shorter hospital stay (7.2 vs. 
8.6 days, P < 0.001), and better quality of life according to 
answers to the European Organisation for Research and 
Treatment of Cancer QLQ-C30 and QLQ-STO22 qual-
ity-of-life questionnaires (P < 0.001). The 5-year disease-
free survival and OS rates in the two groups were similar 
[34].
In 2010, a phase III multicenter RCT conducted by 
the Korean Laparoscopic Gastrointestinal Surgery Study 
Group (KLASS Trial), which included 342 patients ran-
domized to undergo LADG (179 patients) or ODG (163 
patients), showed that the postoperative complication 
rates were 9% (17/179) in the LADG group and 15% 
(24/163) in the ODG group (P  =  0.137), with no sig-
nificant difference in the morbidity (11.6% vs. 15.1%, 
P = 0.137) or mortality (1.12% vs. 0%, P = 0.497) [35].
In Japan, two large RCTs with GC patients based on 
a prior trial (JCOG0703) are ongoing [36]. One RCT is 
evaluating the noninferiority of OS for LADG compared 
with ODG (JCOG0912) [37]. The other is a phase II/III 
RCT by the Japanese Laparoscopic Surgery Study Group, 
evaluating morbidity and recurrence-free survival in 
500 gastric cancer patients who will be registered and 
undergo LADG or ODG (JLSSG0901) (Table 2).
Conclusions
For some time, the optimal method of node dissection 
has been a subject of intense debate. However, three 
RCTs comparing D2 and D1 dissection have provided 
some consensus. D2 dissection may be more beneficial 
than D1 dissection. Given the results of the Italian Gas-
tric Cancer Study Group study, selecting GC patients for 
more extensive surgery may be possible. Surgery beyond 
D2 dissection is not useful (JCOG9501).
Pancreatectomy should be avoided for GC since pan-
creas-preserving D2 dissection has been shown to be 
superior to D2 dissection with pancreatectomy [24]. In 
the RCTs in Chile and Korea comparing gastrectomy 
with and without splenectomy, the 5-year OS rates did 
not differ. These results may encourage performing gas-
trectomy with D2 dissection that preserves the spleen. 
Results of a JCOG RCT designed to assess the noninfe-
riority of spleen preservation will be helpful in resolving 
this issue.
LADG is another advance in GC treatment that pro-
duces results similar to those of ODG. Many RCTs have 
demonstrated lower blood loss with and earlier recovery 
from LADG than with/from ODG. However, operation 
time has been longer for LADG than for ODG. In some 
studies, LADG yielded fewer nodes than ODG. Ongoing 
studies will settle this issue. Additionally, robot-assisted 
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surgery for GC is becoming prevalent, and many studies 
of neoadjuvant and adjuvant chemotherapy and radiation 
therapy are in progress, though without sufficient evi-
dence. In the future, the results of ongoing studies may 
alter operating procedures (Table 3).
In conclusion, GC surgery techniques have evolved 
over time. D2 dissection without pancreatectomy (and 
even with splenectomy) has been embraced as the stand-
ard, and further developments will bring about the use of 
robotics.
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